Immunodeficiency clinical trials

Explore recruiting immunodeficiency clinical trials.

Recruiting immunodeficiency studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Immunodeficiency trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Venetoclax and Dexamethasone in translocation (11;14) positive relapsed and refractory multiple myeloma (VICTORIA)

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Single Arm, Open Label Clinical Study of Hematopoietic Stem Cell Gene Therapy with Cryopreserved Autologous CD34+ Cells Transduced with Lentiviral Vector encoding WAS cDNA in Subjects with Wiskott-Aldrich Syndrome (WAS)

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation Antigen×CD3–Directed Bispecific Antibody Therapy

Hungary, Germany, Greece, Netherlands, Austria, Poland +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Assessment of clozapine-related immunodeficiency effect in Parkinson's disease patients (CLOZIDPD)

France

Therapeutic use (Phase IV) EU CTIS Study details

Long-term Safety and Tolerability of TAK-881 in Subjects with Primary Immunodeficiency Diseases (PIDD)

Greece, Germany, Poland, Netherlands, Denmark, Czechia +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of leniolisib for immune dysregulation in patients with primary immunodeficiency

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Immunodeficiency trials by city

Immunodeficiency in Toronto Immunodeficiency in Vancouver Immunodeficiency in Montreal Immunodeficiency in Calgary Immunodeficiency in Edmonton Immunodeficiency in Ottawa Immunodeficiency in Winnipeg Immunodeficiency in Quebec City Immunodeficiency in Hamilton Immunodeficiency in Kitchener Immunodeficiency in London Immunodeficiency in Halifax Immunodeficiency in New York Immunodeficiency in Los Angeles Immunodeficiency in Chicago Immunodeficiency in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease